高視 GAUSH 高视医疗科技有限公司 Gaush Meditech Ltd (於開曼群島註冊成立的有限責任公司) 股份代號 : 2407 科技締造 光明視界 **2024 GAUSH 目錄 公司概況2 公司資料3 財務摘要5 管理層討論及分析6 其他資料 19 獨立審閱報告 25 中期簡明綜合損益表 26 中期簡明綜合全面收益表 27 中期簡明綜合財務狀況表 28 中期簡明綜合權益變動表 30 中期簡明綜合現金流量表 31 中期簡明綜合財務資料附註 33 釋義 52 GAUSH 公司概況 高視醫療科技有限公司是一家於2017年11月1日根據開曼群島法律註冊成立的獲豁免有限公司，並於2022 年12月12日在聯交所主板上市。 憑藉逾20年的業績記錄，高視醫療作為中國眼科醫療器械市場領先參與者，開發及經銷廣泛的眼科醫療器 械及耗材，亦向最終客戶提供相關技術服務。本集團的產品組合包括本集團開發及製造的自有產品以及本 集團所經銷的品牌夥伴的經銷產品，涵蓋使用眼科醫療器械進行診斷、治療或手術的所有七個眼科亞專科， 即眼底病、白內障、屈光不正、青光眼、眼表疾病、視光及兒童眼科。 2024年中期報告 2 公司資料 董事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司） （股 份 代 號：2407） 截至2024年6月30日止六個月的中期業績公告 | --- | |---------------------------------------------------------------------------------------------------------------------------------------| | | | 中期業績摘要 | | 截至 2024 年 6 月 30 日止六個月，本集團錄得收入人民幣 642.0 百萬元，較 同期的收入人民幣 700.7 百萬元減少 8.4% 。 | | 截至 2024 年 6 月 30 日止六個月，本集團錄得利潤淨額人民幣 26.9 百萬元，較 2023 年同期錄得利潤淨額人民 ...

ai1713787694134_Gaush AR2023 Cover V15_24.5mm OP.pdf 1 22/4/2024 下午8:08 年報 2023 ANNUAL REPORT 2023 (Incorporated in the Cayman Islands with limited liability) Stock Code : 2407 年報 2023 ANNUAL REPORT 科技締造 光明視界 高視GAUSH (於開曼群島註冊成立的有限責任公司) 股份代號 : 2407 科技締造 光明視界 | --- | --- | --- | |-------|--------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 目錄 | | | | 公司概況 | 2 | | | 公司資料 | 3 | | | | | | | 財務摘要 | 5 | | | 主席報告 | 6 | | | | | | | 管理層討論及分析 | 8 | | | 董事及高級管理 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司） （股 份 代 號：2407） 截至2023年12月31日止年度的 年度業績公告 | --- | --- | |-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ...

ai169500709820_Gaush IR2023 Cover V10_7.5mm OP.pdf 1 18/9/2023 上午11:18 高視GAUSH (Incorporated in the Cayman Islands with limited liability) Stock Code : 2407 中期報告 2023 INTERIM REPORT (於開曼群島註冊成立的有限責任公司) 股份代號 : 2407 INTERIM REPORT 2023 2023 中期報告 目錄 公司概況 2 公司資料 3 財務摘要 5 管理層討論及分析 6 其他資料 20 獨立審閱報告 25 中期簡明綜合損益表 26 中期簡明綜合全面收益表 27 中期簡明綜合財務狀況表 28 中期簡明綜合權益變動表 30 中期簡明綜合現金流量表 31 中期簡明綜合財務資料附註 33 釋義 53 公司概況 高視醫療科技有限公司是一家於二零一七年十一月一日根據開曼群島法律註冊成立的獲豁免有限責任公司， 並於二零二二年十二月十二日在聯交所主板上市。 本集團的主營業務為研發、生產及經銷廣泛的眼科醫療設備及耗材，亦向最終客戶提供相關技術服務。 ...

[41 -> 70] 各位参议师以及投资者朋友们,大家上午好。欢迎各位出席高市医疗2023年度中期业绩发布会。首先,我们有请田圆女士做开场介绍。大家好,欢迎各位参会。首先介绍一下,参加本次发布会的公司管理层代表有高市医疗创始人、董事长兼首席执行官高铁塔先生、联席CEO兼执行董事刘新伟先生、 [70 -> 96] 以及首席财务官执行董事,尽涉及内在风险及不确定因素,可能导致实际业绩偏离当前的预期。有关该等风险及不确定因素的详细论述,请参阅高市医疗向香港交易所递交的最新公告内容。 [96 -> 126] 本次会议中所提供的一切紧张性陈述均基于我们认为截至今日合理的假设高市医疗并不承担更新该等陈述的任何义务除非适用法律另有规定本次讨论还包含某些非国际财务报告准则的财务措施仅供比较之用稍后刘兴伟先生将首先向大家介绍高市医疗的业务发展情况及未来展望第二部分由李文琪女士帮我们回顾公司的财务表现 [126 -> 156] 在管理层的讲解之后 在管理层的讲解之后 我们将会举行一个简单的问答环节 我们将会举行一个简单的问答环节 各位如需与管理层进行线上提问 各位如需与管理层进行线上提问 可通过举手语音提问或文字提问 可通过举手 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司） （股 份 代 號：2407） 截至二零二三年六月三十日止六個月的 中期業績公告 | --- | --- | |--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 中期業績摘要 | | | 截至二零二三年六月三十日止六個月，本集團錄得收入人民幣 700.7 百萬元， 較 ...

Financial Performance - Revenue for 2022 was RMB 1,253.8 million, a decrease of 3.4% compared to RMB 1,298.2 million in 2021[6] - Net loss for 2022 was RMB 352.7 million, an increase of 84.1% compared to RMB 191.6 million in 2021[6] - Adjusted net profit (non-IFRS measure) for 2022 was RMB 157.3 million, a decrease of 8.2% compared to RMB 171.3 million in 2021[6] - Basic loss per share for 2022 was RMB 3.61, an increase of 81.4% compared to RMB 1.99 in 2021[6] - Revenue for 2022 was RMB 1,253.8 million, a decrease of 3.4% compared to the previous year[11] - Gross profit increased to RMB 625.3 million in 2022, up by 2.6% year-over-year[11] - Sales of ophthalmic medical equipment decreased to RMB 641.3 million in 2022 from RMB 718.7 million in 2021[12] - Sales of ophthalmic medical consumables increased to RMB 411.8 million in 2022 from RMB 408.4 million in 2021[12] - Technical service revenue rose to RMB 190.1 million in 2022 from RMB 161.6 million in 2021[12] - Revenue decreased by 3.4% from RMB 1,298.2 million in 2021 to RMB 1,253.8 million in 2022 due to the impact of COVID-19, particularly in December 2022[24][26] - Sales of ophthalmic medical equipment decreased by RMB 77.4 million, partially offset by an increase in technical service revenue of RMB 28.5 million and ophthalmic medical consumables revenue of RMB 3.4 million[26] - Gross profit increased by 2.6% to RMB 625.3 million in 2022, with gross margin improving from 46.9% in 2021 to 49.9% in 2022[29] - Gross margin for ophthalmic medical consumables increased to 55.6% in 2022 from 51.2% in 2021, while gross margin for technical services rose to 48.0% from 43.4%[30] - Sales and distribution expenses decreased slightly by 0.9% to RMB 187.8 million in 2022, accounting for 15.0% of revenue compared to 14.6% in 2021[32] - Administrative expenses increased by 11.2% to RMB 146.2 million in 2022, driven by higher personnel costs and listing-related expenses[33] - Other income and gains decreased significantly to RMB 21.1 million in 2022 from RMB 77.9 million in 2021, mainly due to foreign exchange losses of RMB 172.5 million[31] - Financing costs decreased by 48.9% from RMB 83.5 million in 2021 to RMB 42.7 million in 2022, primarily due to the repayment of interest-bearing loans[34] - R&D costs increased by 74.8% from RMB 23.5 million in 2021 to RMB 41.1 million in 2022, driven by team expansion and R&D center upgrades[35] - The fair value loss on convertible redeemable preferred shares decreased from RMB 375.6 million in 2021 to RMB 307.4 million in 2022 due to changes in the company's valuation[36] - Other expenses surged from RMB 21.7 million in 2021 to RMB 196.4 million in 2022, mainly due to increased exchange losses on preferred shares[36] - Income tax expenses rose by 44.8% from RMB 53.6 million in 2021 to RMB 77.6 million in 2022, reflecting higher taxable profits[37] - The company recorded a net loss of RMB 352.7 million in 2022, compared to a net loss of RMB 191.6 million in 2021[38] - Adjusted net profit (non-IFRS) decreased by 8.2% from RMB 171.3 million in 2021 to RMB 157.3 million in 2022, impacted by pandemic control policies and increased R&D expenses[39] - Inventory increased by 17.1% from RMB 240.1 million in 2021 to RMB 281.1 million in 2022, with inventory turnover days rising from 129 days to 155 days[41] - Trade receivables decreased by 4.7% from RMB 180.2 million in 2021 to RMB 171.7 million in 2022, with turnover days remaining stable at 50-51 days[42] - Goodwill increased by 2.7% from RMB 882.7 million in 2021 to RMB 906.9 million in 2022, mainly due to exchange rate fluctuations between RMB and EUR[45] - Intangible assets decreased by 8.2% from RMB 303.9 million as of December 31, 2021, to RMB 278.9 million as of December 31, 2022, primarily due to accumulated amortization[46] - Cash and cash equivalents increased by 18.5% from RMB 609.0 million as of December 31, 2021, to RMB 721.5 million as of December 31, 2022, driven by IPO proceeds and increased operating cash flow[47] - Capital expenditures increased by 71.2% from RMB 28.0 million in 2021 to RMB 48.0 million in 2022, mainly for production-related equipment and daily renovation expenses[49] - The asset-liability ratio improved to 50.9% as of December 31, 2022, compared to a negative 151.8% as of December 31, 2021, due to the elimination of net liabilities under IFRS[50] - The company repaid a total of EUR 11.25 million of long-term loans from Swiss banks and EUR 25.0 million of mezzanine financing loans in 2022[47] - The effective annual interest rate for bank and other borrowings ranged from 1.50% to 7.00% as of December 31, 2022, with remaining loan terms ranging from less than one year to three years[48] - The company recorded a foreign exchange gain of RMB 24.5 million in 2022, compared to a loss of RMB 58.6 million in 2021, due to fluctuations in the Euro exchange rate[52] - The company has no significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures as of December 31, 2022[54] - The company has no significant future plans for investments or capital assets beyond those disclosed in the annual report and prospectus[55] - The company maintains a robust liquidity position with sufficient cash and bank balances to meet operational needs and support expansion plans[47] - The company's global offering generated net proceeds of approximately HKD 284.71 million after deducting underwriting fees, commissions, and other estimated expenses[78] - Net proceeds of HKD 284.71 million were utilized as of December 31, 2022, with HKD 216.27 million remaining unused[80] - 38.2% of net proceeds (HKD 108.76 million) allocated to R&D and patent commercialization, expected to be fully utilized by December 11, 2024[80] - 29.0% of net proceeds (HKD 82.56 million) allocated to capacity expansion and manufacturing enhancement, expected to be fully utilized by December 11, 2024[80] - 9.5% of net proceeds (HKD 27.05 million) allocated to sales and marketing expansion, expected to be fully utilized by December 11, 2024[80] - 10.6% of net proceeds (HKD 30.18 million) allocated to working capital and general corporate purposes[80] - 12.7% of net proceeds (HKD 36.16 million) allocated to repayment of interest-bearing borrowings[80] - Additional net proceeds of HKD 1.77 million were generated from the partial exercise of the over-allotment option on January 9, 2023[81] - The company had distributable reserves of approximately RMB 822.2 million as of December 31, 2022[87] - The company had a total of 790 employees as of December 31, 2022, with total employee costs amounting to RMB 288.4 million for the year[94] - The company's core values emphasize employee development, with a focus on training and skill enhancement across various levels and positions[94] - The company operates a defined contribution retirement plan, with contributions made based on a percentage of employee salary costs[95] - Liu Xinwei was appointed as Co-CEO and his annual salary was adjusted from RMB 1,070,000 to RMB 1,170,000 effective January 10, 2023[96] - Zhang Jianjun resigned as President and was appointed as Honorary President, with his annual salary adjusted from RMB 1,160,000 to RMB 800,000 effective January 10, 2023[96] - Gao Tieta holds a 42.76% stake in the company through controlled corporate interests, owning 63,263,528 shares[98] - Zhang Jianjun holds a 4.81% stake in the company through controlled corporate interests, owning 7,112,360 shares[98] - Zhao Xinli holds a 2.32% stake in the company through controlled corporate interests, owning 3,436,116 shares[98] - Liu Xinwei holds a 0.65% stake in the company through controlled corporate interests, owning 955,879 shares[98] - No directors or senior executives have rights to acquire shares or debentures of the company or any other corporate body as of December 31, 2022[100] - GT HoldCo holds 63,263,528 shares, representing 42.76% of the company's issued share capital[102] - OrbiMed Asia directly holds 18,039,426 shares, representing 12.19% of the issued share capital[103] - Cuprite Gem directly holds 11,375,840 shares, representing 7.69% of the issued share capital[104] - GT HoldCo had 38,472,296 shares mortgaged to Credit Suisse for a HKD 185,000,000 loan, which was fully repaid by April 6, 2023[103] - The company has no significant legal proceedings or claims pending or threatened against it as of December 31, 2022[109] - The company maintains a minimum public float of 25% of its total issued share capital, as required by the Hong Kong Stock Exchange[111] - Ernst & Young was appointed as the auditor for the fiscal year ending December 31, 2022, and will be proposed for re-election at the upcoming annual general meeting[112] - The company has adopted the Corporate Governance Code as its own governance standard and has complied with all applicable code provisions during the reporting period[114] - The company emphasizes a culture of integrity, ethical behavior, and compliance, with standards integrated into employee training materials and policies such as the Code of Conduct and Anti-Corruption Policy[116] - The company is committed to employee development, workplace safety, diversity, and sustainability, aiming for long-term, stable, and sustainable growth[117] - The Board of Directors consists of 4 executive directors, 2 non-executive directors, and 3 independent non-executive directors, with one independent director possessing appropriate professional qualifications in accounting or financial management[119] - Independent non-executive directors play a crucial role in providing impartial views on strategy, performance, and controls, ensuring shareholder interests are considered[121] - The company has adopted a Board Diversity Policy to enhance efficiency and maintain high governance standards, considering factors such as gender, age, cultural background, and professional experience[122] - The Board's current composition includes directors with diverse expertise in medicine, business administration, finance, and accounting, aged between 41 and 62[122] - The company has implemented a Board Independence Evaluation Mechanism to ensure strong independent elements and effective decision-making[121] - The company has arranged appropriate liability insurance for directors, with coverage reviewed annually[118] - The Board has delegated specific oversight responsibilities to three committees: Audit, Remuneration, and Nomination Committees[118] - The company aims to appoint at least one female director within one year of the listing date and achieve a target of no less than 20% female representation on the board within five years, subject to satisfaction of candidates' qualifications and experience[123] - As of December 31, 2022, the company had 790 full-time employees, with female employees accounting for approximately 36.7% of the workforce, achieving a relatively balanced gender ratio[123] - The company has set measurable goals, including having at least one female member in the senior management team and maintaining at least 35% female representation among full-time employees[123] - Li Wenqi, a female executive, was appointed as the company's CFO in January 2023, responsible for the group's overall financial management[123] - The company provides necessary induction training and regular updates to newly appointed directors to ensure they are well-informed about the company's operations and regulatory responsibilities[124] - Directors are encouraged to participate in continuous professional development programs to enhance their knowledge and skills, with external legal counsel providing training on regulatory updates[124] - The Chairman and CEO roles are held by the same individual, Gao Tieta, due to his extensive experience and understanding of the company's business, which facilitates strategic execution and information flow[126] - The company's board consists of experienced and talented individuals, with decisions requiring approval by at least a majority of the directors, ensuring checks and balances[126] - Executive and non-executive directors have service contracts with the company, initially for three years from the listing date, renewable under applicable laws and regulations[127] - Independent non-executive directors have appointment letters with the company, also initially for three years from the listing date, renewable under applicable laws and regulations[127] - The company will hold at least four regular board meetings in the fiscal year ending December 31, 2023[128] - The board chairman will hold at least one meeting with independent non-executive directors without the presence of other directors in the fiscal year ending December 31, 2023[128] - The audit committee reviewed the audited consolidated financial statements and annual results for the year ended December 31, 2022, during its meeting on March 31, 2023[133] - The audit committee also reviewed the effectiveness of the company's financial reporting, risk management, and internal control systems during the March 31, 2023 meeting[133] - The nomination committee is responsible for reviewing the board's structure, size, and composition at least annually and making recommendations for changes to align with the company's corporate strategy[134] - The nomination committee is tasked with identifying and evaluating candidates for board and senior management positions, including assessing the balance of skills, knowledge, and experience on the board[134] - The board retains decision-making authority over all significant matters, including policy approval, overall strategy, budgets, internal controls, risk management systems, and major transactions[130] - The company has adopted a code of conduct for securities transactions by directors and employees, with terms no less stringent than the standard code[129] - The board is collectively responsible for corporate governance, including reviewing and monitoring compliance with legal and regulatory requirements[131] - The audit committee is responsible for overseeing the company's financial reporting system, risk management, and internal control systems[132] - The company held its first nomination committee meeting on March 31, 2023, where it reviewed the composition of the board and its committees, recommended the re-election of retiring directors, and proposed the appointment of Dr. Alexey Nikolaevich Simonov as Chief Technology Officer[135] - The nomination committee evaluates candidates based on diversity factors including gender, age, cultural and educational background, race, professional experience, skills, knowledge, and tenure, as well as their potential contributions to shareholder value[137] - The nomination process includes consulting various sources, assessing candidates through interviews and background checks, and making recommendations to the board, which has the final authority to appoint directors[138] - The remuneration committee reviewed and recommended the compensation for directors and senior management for the year ending December 31, 2023, including adjustments for some executive directors and senior management[140] - The company's director remuneration policy includes a fixed component (base salary) and a variable component (discretionary bonuses and other incentives), considering factors such as experience, responsibility level, individual performance, and market conditions[141] - The total remuneration for audit and non-audit services provided by the auditor in 2022 amounted to RMB 19,519 thousand, with audit services accounting for RMB 17,587 thousand and non-audit services for RMB 1,932 thousand[145] - The company has established a robust risk management and internal control system, which is reviewed annually by the Board to ensure effectiveness and compliance with legal and regulatory requirements[150] - The company has adopted an anti-corruption policy and a whistleblowing policy to promote ethical behavior, compliance, and good corporate governance, with no significant fraud or misconduct reported for the year 2022[147][148] - The company maintains a high level of corporate governance, with monthly updates provided to the Board on the group's performance, status, and prospects[144] - The company has implemented an insider information management system to ensure timely disclosure of material information and strict control over information dissemination[149] - The company's internal audit function plays a key role in monitoring internal governance, with findings reported to the Audit Committee and, if necessary, to the Board[149] - The company's risk management system includes clear division of responsibilities and authority, regular compliance training for employees, and mechanisms for identifying and mitigating potential risks[149] - The company's ESG-related resources, staff qualifications, training programs, and budgets are deemed sufficient by the Board, with ESG risks included in the risk management framework[150] - The company's corporate governance framework emphasizes high standards of integrity, transparency, and ethical business practices, supported by policies such as the anti-corruption and whistleblowing policies[146][147] - The company's financial statements for 2022 were prepared in accordance with applicable standards, with no significant uncertainties identified that could cast doubt on the group's ability to continue as a going concern[144] - The company has no specific dividend policy or predetermined payout ratio, and future dividend payments will be determined by the board based on profits, cash flow, financial condition, capital requirements, and other relevant factors[152] - The company held its IPO on December 12, 2022, and has not yet held an annual general meeting since listing[153] - The company has established multiple channels for shareholder communication, including annual reports, interim reports, circulars, regular announcements

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司） （股 份 代 號：2407） 截至2022年12月31日止年度的 年度業績公告 | --- | --- | |--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 年度業績摘要 | | 2021 | 本集團截至 2022 年 12 月 31 日止年度的收入為人民幣 1,253. ...